Skip to content
value.today
Access Pharmaceuticals Inc. logo

Access Pharmaceuticals Inc.

Total raised
$16 M
2 rounds on record
Latest round
$10 M
Oct 2012
First round on record
Nov 2011
Today
Went public
See the company page

Access Pharmaceuticals Inc. is listed today as Abeona Therapeutics Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Access Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2015$14 MPrivate placement after listing$10 to $50 million

Access Pharmaceuticals Inc.: Private sale, May 2015

Investors in this round

17 investors had bought by the notice of Jun 1, 2015: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $23 M offered; $9 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen B. Thompson · Executive Officer · Mr. Thompson is the Vice President - Finance, Treasurer and Secretary of the Issuer.
  • Steven H. Rouhandeh · Executive Officer · Mr. Rouhandeh is the Executive Chairman of the Issuer.
  • Tim B. Miller · Executive Officer, Director · Dr. Miller is the President and Chief Executive Officer of the Issuer.
  • Jeffrey H. Davis · Director
  • Mark J. Ahn · Director
  • Mark J. Alvino · Director
  • Stephen B. Howell · Director
  • Todd B. Wider · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Securities valued at $9,000,000 may be issued upon the realization of certain milestones.”
  • On a merger: “The offering is being made in connection with a merger.”

Signed by Stephen B. Thompson, Vice President, Treasurer and Secretary of the Issuer. Source: SEC Form D, newest notice filed Jun 1, 2015. Read the notice at the SEC.

equitySEC
May 2015$10 MPrivate placement after listing$10 to $50 million

Access Pharmaceuticals Inc.: Private sale, May 2015

Investors in this round

2 investors had bought by the notice of May 22, 2015: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,150,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Stephen B. Thompson · Executive Officer
  • Steven H. Rouhandeh · Executive Officer
  • Jeffrey H. Davis · Director
  • Mark J. Ahn · Director
  • Stephen B. Howell · Director
  • Todd B. Widder · Director
  • mark J. Alvino · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H. C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NJ

Signed by Stephen B. Thompson, Vice President, Finance. Source: SEC Form D, newest notice filed May 22, 2015. Read the notice at the SEC.

equity, optionsSEC
Oct 2012$10 MNo. 2$10 to $50 million

Access Pharmaceuticals Inc.: Raise no. 2, Oct 2012

Investors in this round

1 investor had bought by the notice of Nov 2, 2012: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: 1,000 shares of Series B Cumulative Convertible Preferred Stock and warrants to purchase 20,000,000 shares of Common Stock at an exercise price of $0.50 per share.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey B. Davis · Executive Officer, Director
  • Stephen B. Thompson · Executive Officer, Promoter
  • Mark J. Ahn, Ph.D. · Director
  • Mark J. Alvino · Director
  • Stephen B. Howell, M.D. · Director
  • Steven H. Rouhandeh · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering consists of $4,703,000 in cash and the conversion of approximately $5,297,000 of outstanding dividends payable on the Issuer's Series A Preferred Stock.”

Signed by Stephen B. Thompson, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 2, 2012. Read the notice at the SEC.

equitySEC
Nov 2011$6 MNo. 1$2 to $10 million

Access Pharmaceuticals Inc.: Raise no. 1, Nov 2011

Investors in this round

14 investors had bought by the notice of Nov 14, 2011: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$6 M of $6 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Units which consist of one share of Common Stock, a Two & One Half Year Warrant to acquire 0.5 shares of Common Stock at a purchase price of $1.67 per share and a 5 Year Warrant to acquire 0.5 shares
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey B. Davis · Executive Officer, Director · Chief Executive Officer and Director
  • Stephen B. Thompson · Executive Officer · Vice President, Chief Financial Officer, Treasurer and Secretary
  • Esteban H. Cvitkovic, M.D. · Director · Vice Chairman - Europe
  • Mark J. Ahn, Ph.D. · Director
  • Mark J. Alvino · Director
  • Stephen B. Howell, M.D. · Director
  • Steven H. Rouhandeh · Director · Chairman of the Board

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Stephen B. Thompson, Chief Financial Officer. Source: SEC Form D, newest notice filed Nov 14, 2011. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Abeona Therapeutics Inc., its revenue in fiscal 2025 came from these product and service lines: License $3.40 million (58%).

    Annual report (SEC XBRL) · Dec 2025

  • Access Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2015).

    SEC Form D · Jun 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jun 2015

Products and services#

No products or services of Access Pharmaceuticals Inc. are on record.

Investors#

No investor of Access Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.

Largest shareholders today

Institutions holding Abeona Therapeutics Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Access Pharmaceuticals Inc.
NameRoleNamed in
Stephen B. ThompsonMr. Thompson is the Vice President - Finance, Treasurer and Secretary of the Issuer.Jun 2015
Steven H. RouhandehMr. Rouhandeh is the Executive Chairman of the Issuer.Jun 2015
Tim B. MillerDr. Miller is the President and Chief Executive Officer of the Issuer.Jun 2015
Jeffrey B. DavisExecutive officerNov 2012
Jeffrey H. DavisDirectorJun 2015
Mark J. AhnDirectorJun 2015
Mark J. AlvinoDirectorJun 2015
Stephen B. HowellDirectorJun 2015
Tim B. MillerDr. Miller is the President and Chief Executive Officer of the Issuer.Jun 2015
Todd B. WiderDirectorJun 2015
Todd B. WidderDirectorMay 2015
mark J. AlvinoDirectorMay 2015
Jeffrey B. DavisDirectorNov 2012
Mark J. Ahn, Ph.D.DirectorNov 2012
Stephen B. Howell, M.D.DirectorNov 2012
Steven H. RouhandehDirectorNov 2012
Esteban H. Cvitkovic, M.D.Vice Chairman - EuropeNov 2011
Stephen B. ThompsonPromoterNov 2012

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.